314 related articles for article (PubMed ID: 4613968)
1. [Comparative study on Parkopan, Amantadine and L-dopa in the treatment of Parkinson's disease].
Dzudza M; Dzudza D
Med Arh; 1974; 28(4):407-15. PubMed ID: 4613968
[No Abstract] [Full Text] [Related]
2. [Comparison between the effects of L-dopa, prodipine and amantadine on the serum and CSF amino acid levels in Parkinson's disease (author's transl)].
Gründig E; Gerstenbrand F
Wien Klin Wochenschr; 1980 Dec; 92(24):868-71. PubMed ID: 7222702
[TBL] [Abstract][Full Text] [Related]
3. The treatment with L-dopa and amantadine in Parkinson's disease.
Pendefunda G; Pollingher B; Stefanache F; Gavril A; Oprisan C; Merling M; Nemteanu E; Ciunru M; Koropitzer I
Ther Hung; 1975; 23(1):12-6. PubMed ID: 1105871
[No Abstract] [Full Text] [Related]
4. [Modification of Parkinson tremor by budipine. A comparative study with amantadine].
Iizuka J; Fischer R
Nervenarzt; 1986 Mar; 57(3):184-6. PubMed ID: 3515215
[No Abstract] [Full Text] [Related]
5. Is pathological gambling in Parkinson's disease reduced by amantadine?
Lee JY; Kim HJ; Jeon BS
Ann Neurol; 2011 Jan; 69(1):213-4; author reply 214-5. PubMed ID: 21280095
[No Abstract] [Full Text] [Related]
6. Twenty-five years of amantadine therapy in Parkinson's disease.
Danielczyk W
J Neural Transm Suppl; 1995; 46():399-405. PubMed ID: 8821075
[TBL] [Abstract][Full Text] [Related]
7. The L-dopa sparing effect of G 31,406 in the treatment of parkinson's disease.
Couto B; Oliveira C; Mattos JP; Freitas MR
Neurol Neurocir Psiquiatr; 1976; 17(4):285-92. PubMed ID: 798128
[TBL] [Abstract][Full Text] [Related]
8. Drug management of Parkinson's disease.
Kishore A; Snow BJ
Can Fam Physician; 1996 May; 42():946-52. PubMed ID: 8688697
[TBL] [Abstract][Full Text] [Related]
9. Treatment options for early Parkinson's disease.
Stacy M; Brownlee HJ
Am Fam Physician; 1996 Mar; 53(4):1281-7. PubMed ID: 8629572
[TBL] [Abstract][Full Text] [Related]
10. Current therapy of Parkinson's disease.
Ajax T; Rodnitzky R; Dobson J
Iowa Med; 1997 Jan; 87(1):27-9. PubMed ID: 9029838
[No Abstract] [Full Text] [Related]
11. [Initiation of treatment in Parkinson disease].
Ghika J
Praxis (Bern 1994); 1995 Sep; 84(38):1018-20. PubMed ID: 7481298
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of Parkinson's disease.
Burton K; Calne DB
Neurol Clin; 1984 Aug; 2(3):461-72. PubMed ID: 6152482
[TBL] [Abstract][Full Text] [Related]
13. [Therapy of Parkinson's disease. Practical criteria of treatment].
Casacchia M; Carolei A; Zamponi A; Agnoli A; Fazio C
Recenti Prog Med; 1976 May; 60(5):567-84. PubMed ID: 14360
[No Abstract] [Full Text] [Related]
14. Parkinson's disease.
Barboi AC; Goetz CG
Clin Neuropharmacol; 1999; 22(4):184-91. PubMed ID: 10442246
[No Abstract] [Full Text] [Related]
15. Amantadine in Parkinson's disease: pro and contra.
Greulich W; Fenger E
J Neural Transm Suppl; 1995; 46():415-21. PubMed ID: 8821077
[TBL] [Abstract][Full Text] [Related]
16. Amantadine and other antiglutamate agents: management of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S13-22. PubMed ID: 12211136
[No Abstract] [Full Text] [Related]
17. Parkinson's disease: drug therapy.
Oertel WH; Quinn NP
Baillieres Clin Neurol; 1997 Apr; 6(1):89-108. PubMed ID: 9426870
[TBL] [Abstract][Full Text] [Related]
18. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
Mercuri NB; Bernardi G
Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
[TBL] [Abstract][Full Text] [Related]
19. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
Hill MP; Ravenscroft P; Bezard E; Crossman AR; Brotchie JM; Michel A; Grimée R; Klitgaard H
J Pharmacol Exp Ther; 2004 Jul; 310(1):386-94. PubMed ID: 15004218
[TBL] [Abstract][Full Text] [Related]
20. [Recent aspects of Parkinson therapy].
Jörg J; Janssen A
Z Gerontol; 1987; 20(1):38-43. PubMed ID: 3107231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
